b cell replacement as diabetes treatment is a desirable therapeutic approach. An existing b cell source is human cadaveric pancreatic islets; however, lifetime immunosuppressive drug administration and organ scarcity demand an alternative supply (1, 2) . The ultimate solution would be generation of insulin-producing b-like cells that mimic insulin production and release the function of endogenous pancreatic b cells. Although it is very progressive, in vitro b cell generation from induced pluripotent stem cells or embryonic stem cells (3, 4) has potentially limited clinical application because (1) the existing genetic diabetic predisposition could affect cell pluripotency (5, 6) ; (2) the reprogramming process and subsequent expansion of induced pluripotent stem cells can cause genetic and epigenetic abnormalities, possibly triggering an autologous immune response (7, 8) ; and (3) it requires extensive multistep procedures to produce and maintain a sufficient amount of b cell mass and for transplantation (9) .
An alternative strategy is in vivo direct reprogramming into b-like cells from extrapancreatic tissues, including the liver, by force-expressing insulin-activating key b cell developmental transcription factors such as pancreatic and duodenal homeobox gene 1 (Pdx1), basic helix-loop-helix transcription factor (Neurod1), and MAF basic leucine zipper (Mafa) (10) (11) (12) (13) . Pdx1, a key pancreatic developmental regulator, was reported to be capable of hepatic insulin production transiently but not glucose responsiveness (10) . Neurod1, an endocrine specification regulator, showed higher efficacy in liver insulin production than did Pdx1, but glucose-stimulated insulin secretion was negligible (11) . The addition of the b cell-specific maturation marker Mafa to Pdx1 and Neurod1 demonstrated greatly increased hepatic insulin production capacity, although transient and glucoseunresponsive insulin secretions were not improved (12, 13) . Taken together, previous studies suggest that this three-gene combination [Pdx1, Neurod1, and Mafa (PDA)] was not sufficient to prolong insulin production or to generate glucose-responsive b-like cells (10-13) from the liver and thereby required additional transcription factors.
Insulin enhancer binding protein-1 (Isl1), a member of the LIM-homeodomain family, is a well-known activator of the insulin gene (14, 15) and is essential for the development of the pancreas (16) . It also plays a crucial role in the proliferation, maturation, and functional maintenance of pancreatic islet cells, including b cells (17) (18) (19) (20) . b cell specific Isl1-deficient mice had shown failure in b cell functional maturation and consequently developed diabetes (17, 19) . In particular, Isl1 was reported to interact with NeuroD to synergistically activate insulin transcription (21, 22) and to directly regulate the gene transcription of Mafa (17) and Pdx1 (19) . This supports the approach of Isl1 as a key extrapancreatic insulin-producing factor, which was first introduced by Kojima et al. (23) in a study of the immature rat intestinal stem cell (IEC-6). Single overexpression of Pdx1 in IEC-6 failed to generate insulinproducing cells, which was resolved by additional treatments of Isl1 (23) . However, the role of Isl1 in generating b cells by directly converting mouse liver has not been investigated.
In this study, we report a comparative gene-expression analysis of PDA-driven liver insulin-producing cells to discover an additional element (i.e., Isl1b, the Isl1 splicing variant). We then demonstrate that the adenoviral expression of Isl1b in combination with PDA in mouse liver improved insulin production and glucose-responsive insulin secretion.
Materials and Method

Ethics statement/animals
All experiments were conducted according to the relevant Japanese and institutional laws and guidelines and were authorized by the University of Tsukuba animal ethics committee (authorization number 13-072). The purchase and maintenance of insulin promoter-luciferase transgenic (MIP-Luc-VU) mice [FVB/N-Tg(ins-luc)-VUPwrs/J, #JAX:007800] were described previously (13, 24) . Insulin promoter-GFP transgenic (MIP-GFP) mice expressing green fluorescent protein under mouse insulin 1 promoter were kindly gifted from Dr. Manami Hara (The University of Chicago, Chicago, IL) and maintained by breeding with Jcl:ICR mice (the Institute of Cancer Research, Clea Japan, Tokyo, Japan) (13, 25) . Both male and female mice were equally subjected to this study. Mice were euthanized with carbon dioxide gas at the appropriate time points.
Adenovirus production and injection
Recombinant adenoviruses expressing GFP (Ad-GFP), LacZ (Ad-LacZ), polycistronic mouse Pdx1, Nuerod1, and Mafa (Ad-PDA), and mouse Isl1b (Ad-Isl1b) were generated using the ViraPower Adenoviral Gateway Expression Kit (Life Technologies, Carlsbad, CA) as previously described (13) . Polycistronic PDA is linked through P2A and T2A as follows: Pdx1-P2A-Neurod1-T2A-Mafa. Isl1a, Isl1b, and Elf3 were cloned from MIN6 complementary DNA (cDNA). Isl1b was confirmed by negative polymerase chain reaction (PCR) amplification from 69 missing base pair sequences in splicing variants. Virus propagation, purification, and titer determination were carried out following previously published methods (13) . The efficacious adenoviral gene transfer delineates the virus titer of 2.5 3 10 9 infectious units. Adenovirus was injected into 7-to 8-week-old mice through the tail vein at free fed status.
Fluorescence-activated cell sorting of GFP-expressing liver cells
At day 7 of adenoviral injection into MIP-GFP mice (25) , liver perfusion was conducted under anesthesia. A 37°C prewarmed 0.5-mM EGTA-Hanks buffer (Gibco, Life Technologies) was perfused through the hepatic portal vein, followed by 1 mg/mL of collagenase II (Gibco) containing 5 mM of CaCl 2 -Hanks buffer. The liver was dissected and chopped into small pieces by using scissors, washed with cold Hanks buffer, and filtered through 70 mm of cell strainer (BD Biosciences, San Jose, CA). Collected liver cells were centrifuged at 1000 rpm for 1 minute; supernatant was discarded to remove blood cells. Cell pellets were washed twice with cold Hanks buffer. At final washing, cell pellets were resuspended with 2% fetal bovine serum, 2 mM of EDTA, and Dulbecco's modified Eagle medium (all Gibco) and subjected to fluorescence-activated cell sorting (Moflo XDP; Beckman, Brea, CA) by GFP expression.
Microarray analysis
Total RNA was extracted from three MIP-GFP mice and pooled by equal RNA concentrations to synthesize a single cDNA sample from each mouse. Liver and pancreatic islets pooled from three mice without adenoviral infection were used as negative and positive controls, respectively. Pancreatic islets were isolated by the standard collagenase digestion protocol using Collagenase Type V (Wako, Osaka, Japan) and then handpicked (26) . The NucleoSpin RNA kit (Macherey-Nagel, Düren, Germany) was used to isolate RNA from collected tissues. First-cycle cDNA, complementary RNA, and secondcycle cDNA were synthesized according to the protocol of the Ambion WT Expression Kit (Life Technologies). cDNA was fragmented and labeled using the GeneChip WT Terminal Labeling and Control Kit (Affymetrix, Santa Clara, CA) and hybridized to the GeneChip MoGene-1_0-st-v1 cassettes array (Affymetrix) at 45°C for 17 hours. The GeneChip arrays were scanned using the GeneChip Scanner 3000 (Affymetrix). Image files were created using the GeneChip Command Console (Affymetrix); data were normalized using the Affymetrix Expression Console software. Gene expression values were compared by twofold cutoff. Then gene ID was converted using an open Web-based tool, Galaxy (#SCR006281) (27) , and gene annotation was obtained from the University of California, Santa Cruz, genome browser (28, 29) . 
Plasmid construct and luciferase assay
Previously constructed pGL2/RIPII-251 plasmid was used for luciferase assay (33) . Adenoviral vectors pAd-PDA, pAdIsl1a, pAd-Isl1b, and pAd-Elf3 were cotransfected with pGL2 constructs in 293A cells for 24 hours using polyethylenimine (Polysciences, Inc., Warminster, PA). Luciferase activities were normalized to Renilla luciferase activity according to the Dual Luciferase Reporter Assay System (Promega, Madison, WI).
Western blot
The 293A cells transfected for 24 hours in luciferase assay were lysed with 20 mM Tris-HCl (pH, 7.5); 150 mM NaCl; 1 mM Na 2 EDTA; 1 mM EGTA; 1% NP-40; 1% sodium deoxycholate; 2.5 mM sodium pyrophosphate; 1 mM b-glycerophosphate; 1 mM Na 3 VO 4 ; 1 mg/mL leupeptin; and complete protease inhibitor cocktail (Roche, Basel, Switzerland). Protein concentrations were measured with Coomassie protein assay reagent (Thermo Scientific, Waltham, MA), and 20 mg of protein extracts were run on 10% SDS-polyacrylamide gels, followed by electrophoretic transfer to a polyvinylidene difluoride membrane (Merck Millipore, Burlington, MA). After 1 hour blocking at room temperature with 5% skim milk (Wako), immunoblots were incubated at 4°C in primary antibodies overnight against Pdx1 [Research Resource Identifier (RRID): AB_777178; Abcam, Cambridge, UK], NeuroD (RRID: AB_2282474; Santa Cruz, Texas), MafA (RRID: AB_1279486; Bethyl Laboratories, Montgomery, Texas), Elf3 (RRID: AB_2278132; R&D Systems, Minneapolis, MN), Isl1 (RRID: AB_528315; DSHB, Iowa City, IA), and b-actin (RRID: AB_10697035; MBL, Nagoya, Japan). Blots were then incubated with secondary antibodies for 1 hour at room temperature, and proteins were detected using chemiluminescence HRP substrate (Millipore).
Bioluminescence imaging
At day 0, adenoviruses (Ad-GFP, Ad-PDA, and Ad-Isl1b) were transferred into the MIP-Luc-VU mice (13, 24) . The bioluminescence signals were detected after 5 minutes of D-luciferin injection (Promega) intraperitoneally, with the dosage of 5 mg/kg of body weight using an IVIS spectrum (Caliper Life Sciences, Hopkinton, MA). Bioluminescence images were obtained within 1 minute of integration time. Isometric regions of interest were automatically captured to quantify the signals emitted from the liver by using Living Image software (Xenogen Corporation, Alameda, CA).
Immunohistochemistry
After 1 week of adenoviral treatment, MIP-GFP mice were euthanized to collect the liver. Tissue was fixed in 4% paraformaldehyde on ice for 4 hours, followed by 30% sucrose phosphate buffered saline overnight at 4°C. Fixed liver was embedded in optimum cutting temperature compound (TissueTek, Sakura, Torrance, CA), frozen, and sliced with 5-mm thickness using a cryostat (Leica, Wetzlar, Germany). Primary antibody, anti-Isl1 (RRID: AB_528315; DSHB), was applied to the sections overnight at 4°C, followed by secondary antibody conjugated with Alexa 555 (RRID: AB_2535769; Life Technologies) for 1 hour at room temperature with nuclear staining using 4 0 ,6-diamidino-2-phenylindole (RRID: AB_2307445; Invitrogen, Eugene, OR). Section images were obtained using the Biorevo BZ-9000 microscope (Keyence, Osaka, Japan) and BZ-II Analyzer software (Keyence).
Total liver RNA extraction, cDNA synthesis, and quantitative real-time polymerase chain reaction Total liver RNA was extracted by using standard Trizol RNA extraction method (ISOGEN; Nippon-gene, Toyama, Japan). Following the protocol of the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany), 1 mg of cDNA was synthesized. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed with SYBR Green PCR master mix (Takara, Shiga, Japan) using the Thermal Cycler Dice Real Time System (Takara) to detect gene expression level and was normalized to Hprt. All primer sequences are listed in Table 1 .
Measurement of insulin content
After 7 days of adenovirus treatment, hepatic insulin was extracted using the standard acid-ethanol method as previously described (13, 34) . Hepatic insulin content was measured by an insulin enzyme-linked immunosorbent assay kit (Morinaga, Yokohaman, Japan). Total protein concentration was calculated using Coomassie protein assay reagent (Thermo Scientific) for normalization.
Diabetes induction
A single injection of streptozotocin (STZ) (Wako) was intraperitoneally administered to 5-week-old wild-type mice (ICR mice) to induce diabetes at a dosage of 200 mg/kg of body weight dissolved in 0.1 M citrate buffer (pH, 4.5). Plasma glucose level was measured with a one-touch blood glucometer (Medisafe reader; Terumo, Tokyo, Japan). After 5 days of STZ induction, hyperglycemic mice were selected by examining fasting blood glucose (.200 mg/dL) and fed blood glucose (.400 mg/dL) levels. Fasting blood glucose concentration was measured after 16 hours of fasting; fed blood glucose concentration was measured in the late morning after 1 hour of fasting.
Glucose and hormone assays
After 1 week of STZ induction, diabetic animals were administered one-third of the standard adenovirus titer. At day 7 of adenoviral treatment, the mice were challenged with glucose intraperitoneally after overnight fasting (16 hours) at a dosage of 2 g/kg of body weight, and plasma glucose levels were measured at 0, 15, and 30 minutes and every 30 minutes for 2 hours. Serum insulin was collected at 0 and 30 minutes and measured using an ultrasensitive insulin enzyme-linked immunosorbent assay kit (Morinaga). 
Statistical analyses
All data values are presented as mean 6 standard error of the mean for a minimum of three independent experiments. Unless otherwise specified, probability values were calculated by using the unpaired Student t test or two-way analysis of variance followed by the Tukey honest significant difference test for multiple comparison analysis. P values ,0.05 were considered significant.
Results
Microarray analysis revealed that PDA-driven insulin-producing cells in liver were lacking key b cell markers, requiring another element
To analyze the defects of insulin-producing liver cells generated by the three key transcription factors Pdx1, Neurod1, and Mafa (PDA) at gene level, we injected PDA recombinant adenovirus (Ad-PDA) into transgenic mice that expressed green fluorescent protein under the control of mouse insulin 1 promoter (MIP-GFP) (25) . On the basis of previous results that PDA gene expression persisted after 7 days of infection (13), we isolated GFPexpressing cells in the liver, extracted RNA, and synthesized cDNA from three mice at day 7 of PDA injection [ Fig. 1(a) ]. After confirming adenoviral-mediated PDA gene induction successfully in the mouse liver (Supplemental Fig. 1) , we compared the expression levels of Ins1 and Ins2 in PDA-expressing liver cells (PDA-cells) and pancreatic islets. These data revealed approximately 50-fold differences [ Fig. 1(b) ] and thus indicate that Table 2 . Three independent experiments were performed. Data were analyzed by one-way analysis of variance with the Tukey-Kramer honest significant difference test. *P , 0.05; **P , 0.01; ***P , 0.001. adenoviral overexpression of PDA in the liver is insufficient to activate comparable insulin transcription to mature b cells.
To examine differential gene expression patterns between the PDA-cell and pancreatic islet, we conducted a microarray gene expression analysis (30) [Fig. 1(c) ]. Importantly, PDA-cell did not upregulate most of the b cell hallmark genes, including Nkx2.2, Pax6, Isl1, Ucn3 (4), and probably endogenous Pdx1 [ Fig. 1(c) ]. We then designed special primers that exclusively detect endogenous expression of Pdx1, Neurod1, and Mafa from amplifying the 3 0 UTR region [ Fig. 1(d) ]. qRT-PCR analysis using these endogenous primers further verified that the expression levels of b cell hallmark genes were negligible [ Fig. 1(e) ], indicating that insulin from PDA-cells was mainly induced by ectopic PDA expression. Altogether, these data suggest that the PDA-cell requires other regulators to improve insulin production and/or glucose responsiveness.
Isl1b is one of the key factors for hepatic insulin production in addition to PDA In searching for the additional factor for PDA-cells, we devised a filtering algorithm to select islet-enriched genes that were not upregulated in PDA-cells. . Next, 87 genes were acquired from the overlap of explicit gene expressions in both the pancreas and pancreatic islet cells to eliminate genes expressed only in pancreatic exocrine tissue but not in islets [ Fig.  2(d) ]. The tissue expression pattern was then evaluated, which marked 24 genes as pancreatic islet specific, using the open-source Beta Cell Atlas software (32) [Fig. 2(d) ]. These candidate genes were highly expressed in pancreatic islets but were undetectable in both hepatocytes and PDA-cells [ Fig. 2(e) ], further confirmed by qRT-PCR analysis [ Fig. 2(f) ]. Finally, we selected two transcription factors: Isl1 and Elf3. Because it was reported that splicing variant Isl1 (Isl1b) is a more potent insulin activator than canonical Isl1 (Isl1a) and is confined to b cell lines (35, 36) , we decided to examine Isl1b, too. To verify the effects of these transcription factors on insulin expression, we performed an in vitro insulin promoter assay using rat insulin promoter II (33) because major regulatory elements are most closely shared between rat insulin promoter II and mouse insulin I promoter (Supplemental Fig. 2) . The promoter assay clearly showed that Isl1b had the most additive effect on insulin promoter activity and contrarily Noninvasive monitoring of MIP-Luc-VU mice verified that Isl1b enhanced transcriptional activity of the insulin promoter in vivo To examine the transcriptional activity of the intrahepatic insulin gene in a noninvasive manner, we monitored the bioluminescence emissions from transgenic mice (MIP-Luc-VU) expressing luciferase under the control of the mouse insulin I promoter (24) after adenoviral treatment. We injected adenoviral Isl1b (Ad-Isl1b) into MIP-Luc-VU mice at 8 weeks of age combined with adenoviral PDA (Ad-PDA). We monitored insulin transcriptional dynamics after luciferin injection (5 mg/kg of body weight, intraperitoneal injection) into the Ad-PDA + Isl1b mouse two times per week by detecting hepatic signals emitted from the upper abdomen of the animal [ Fig. 3(a) ]. Transcriptional activity of the insulin promoter of Ad-PDA + GFP peaked at day 3 and gradually disappeared from the liver at day 7 [ Fig. 3(b) and 3(c) ]. In contrast, the insulin transcriptional peak of Ad-PDA + Isl1b was shifted to day 7, and the transcriptional activity lasted .10 days in the liver, indicating that Ad-PDA + Isl1b treatment prolonged insulin production by increasing insulin promoter activity about twofold compared with controls [ Fig.3(c) ]. These in vivo results further support the concept that Isl1b is one of the additional key transcriptional factors for insulin production and extension in combination with PDA.
Isl1b addition enhanced insulin production and secretion in MIP-GFP mice
To further explore the additive effects of Isl1b in vivo, we injected adenoviral PDA + Isl1b and PDA + LacZ into MIP-GFP mice (25) at 8 weeks of age. To first confirm the adenoviral gene transfer in the liver at day 7, we performed immunofluorescent analysis with each antibody including Isl1b, Pdx1, NeuroD, MafA, Insulin, and Glucagon. The results showed that all genes were successfully expressed in the liver (Supplemental Fig. 3A and 3B), and GFP-expressing cells were frequently overlapped with Pdx1, NeuroD, MafA (Supplemental Fig. 3A and  3B) , and Insulin signals (Supplemental Fig. 3C ) but not with Glucagon ( Supplemental Fig. 3D ). Of note, the Isl1b signal was well correlated with GFP-expressing cells, indicating that Isl1b is important for hepatic insulin production [ Fig. 4(a) ]. We then compared PDA, Isl1b, and Ins1/2 levels by qRT-PCR analysis of whole liver RNA from day 7; interestingly, both Ins1/2 and PDA levels were increased by the addition of Isl1b [Fig. 4 (b) and 4(c)] when the same virus titer of Ad-PDA was delivered to each group. Thus, we first assumed that the Isl1b addition would augment hepatic insulin transcriptional activity by increasing GFP-expressing cell numbers and/or transcriptional intensity. To test this possibility, we quantified GFP-expressing cells by fluorescence-activated cell sorting after collagenase liver perfusion, and GFP-expressing cells in Ad-PDA + Isl1b treatment were increased more than 10-fold compared with controls [ Fig. 4(d) ]. Moreover, qRT-PCR analysis of isolated GFP-expressing cells showed that Isl1b expression significantly increased the expression levels of Ins1 and Ins2, suggesting that Isl1b contributes to both qualitative and quantitative hepatic insulin production [ Fig. 4(e) ]. To further evaluate insulin production and secretion properties in mice treated with adenovirus, we measured the contents of both hepatic and plasma insulins. Hepatic insulin contents of Ad-PDA + Isl1b were 1.7-fold higher than with Ad-PDA + LacZ [ Fig. 4(f)] ; the plasma insulin level was 1.9-fold higher in Ad-PDA + Isl1b mice [ Fig.  4(g) ]. Consequently, the blood glucose level was lower in Ad-PDA + Isl1b mice, but none of the mice fell into hypoglycemic shock or exhibited abnormal eating behavior as indicated by insignificant body weight changes (Supplemental Fig. 3E and 3F ). Taken together, these significantly higher hepatic and plasma insulin levels suggest that the ectopic expression of Isl1b resulted in increased amounts of insulin synthesis, processing, and secretion in combination with PDA.
Overexpression of Isl1b activated key b cell gene expressions
To assess gene expression changes of key b cells and hepatocyte markers in the liver of Ad-PDA + Isl1b mice, we performed qRT-PCR analysis using total RNA from the mouse whole liver. Because Ad-PDA + Isl1b treatment resulted in an increase of Pdx1 and Neurod1 compared with Ad-PDA + LacZ treatment [ Fig. 4(b) ], we assumed that Isl1b would activate endogenous expression levels of intrahepatic Pdx1 and Neurod1 as previously reported (19) .
To address this assumption, we again used specifically designed endogenous primers [ Fig. 1(d) ] for b cellspecific genes, such as Pdx1, Neurod1, Mafa, Pax6, and Ucn3, and the a cell-specific marker Gcg [ Fig. 5(a) ]. The results confirmed that overexpression of Isl1b upregulated hepatic endogenous genes of Pdx1, Neurod1, and Pax6 but not endogenous Mafa and Gcg significantly, which could be explained by less abundant Isl1 cofactors present in the liver, Ldb1 (20, 37) and SSBP3 (38) , which are required for potent Mafa activation. Moreover, Ad-PDA + Isl1b treatment markedly increased the messenger RNA levels of b cell functional genes involved in glucose-stimulated insulin secretion, such as Kir6.2, Pc2, Sur1, and Glut2 [ Fig. 5(b) ]. Unexpectedly, Isl1b addition also increased hepatocyte markers, including Alb, Afp, and Hnf4a [ Fig. 5(c) ], suggesting that Isl1b additional treatment did not contribute to liver dedifferentiation at day 7. Taken together, these data indicate that Isl1b assists in obtaining several key b cell markers and functional genes but not in inhibiting liver markers, thereby suggesting a partial effect.
Ad-PDA + Isl1b treatment improved glucose tolerance and responsiveness in mice with diabetes
To determine whether hepatic insulin production induced by Ad-PDA + Isl1b treatment can ameliorate blood glucose levels in diabetic mice, we injected 200 mg/kg Table 1 . Data (n 5 3, each group) were analyzed using one-way ANOVA followed by the Tukey-Kramer HSD test. (b) mRNA levels of Pdx1, Neurod1, and Mafa and Isl1b at day 7 by qRT-PCR from whole liver. CDS primers [ Fig. 1(d) ] were used to detect PDA, which combined both adenovirus gene induction and endogenous expression levels. ) Insulin contents at day 7 of adenovirus-treated mice from (f) the liver or (g) serum. Data were obtained from three mice from each group and analyzed using one-way ANOVA followed by the Tukey-Kramer HSD test. *P , 0.05; **P , 0.01; ***P , 0.001. ANOVA, analysis of variance; DAPI, 4 0 ,6-diamidino-2-phenylindole; FACS, fluorescence-activated cell sorting; HSD, honest significant difference; mRNA, messenger RNA.
of STZ into ICR mice, which caused hyperglycemia (.200 mg/dL of glucose) after 4 days. We treated mice systemically 7 days after STZ injection, with Ad-PDA + LacZ or Ad-PDA + Isl1b adenovirus and monitored fasting blood glucose concentrations for 28 days. Mice treated with Ad-PDA + LacZ initially maintained normal fasting blood glucose levels for 1 week but progressively increased their fasting blood glucose levels [ Fig. 6(a) ]. In contrast, mice treated with Ad-PDA + Isl1b showed a remarkable decrease in blood glucose levels from 400 mg/dL to ,100 mg/dL after adenoviral treatments and maintained blood glucose levels below 200 mg/dL for 2 weeks, which remained at ;200 mg/dL for 1 month [ Fig. 6(a) ]. The blood glucose area under the curve clearly showed that Ad-PDA + Isl1b treatment ameliorated blood glucose levels more efficiently than Ad-PDA + LacZ [ Fig. 6(b) ]. At 28 days, we confirmed complete b cell ablation by demonstrating negligible pancreatic insulin contents from adenoviraltreated diabetic mice (Supplemental Fig. 4) , which therefore eliminated residual b cell effects. Because Ad-PDA + Isl1b treatment induced more mature and biologically active hepatic insulin production and secretion, we concluded that hepatic insulin production induced by Ad-PDA + Isl1b decreased blood glucose levels in STZ-induced diabetic mice.
To assess the contribution of Ad-PDA + Isl1b treatments to glucose homeostasis, we performed an intraperitoneal glucose tolerance test (2 g of glucose/kg) after 7 days of adenoviral treatments in STZ-induced diabetic mice [ Fig. 6(c) ]. Compared with Ad-PDA + LacZ-treated mice, mice treated with Ad-PDA + Isl1b had marked improvement in glucose clearance after glucose injection [ Fig. 6(c) ] as illustrated by the area under the curve [ Fig. 6(d) ].
To further characterize glucose-stimulated hepatic insulin production and secretion in mice treated with Ad-PDA + LacZ or STZ-induced diabetic mice treated with Ad-PDA + Isl1b, we measured fasting and glucose-stimulated hepatic insulin levels. We found that the levels of hepatic insulin in mice treated with Ad-PDA + Isl1b were 1.7-and 2.7-fold higher in both fasting and glucose-stimulated status than mice treated with Ad-PDA + LacZ [ Fig. 6(e) ]. Furthermore, mice treated with Ad-PDA + Isl1b secreted 1.6-fold more insulin after glucose stimulation [ Fig. 6(e) ], suggesting that Isl1b expression increases the capacity and glucose responsiveness of hepatic insulin-producing cells to release insulin after glucose stimulation.
Discussion
In this study, we demonstrated that an additional insulinproducing factor, Isl1b, in combination with PDA extended the overall duration of hepatic insulin transcriptional activity by increasing both insulin transcriptional activity and insulin-producing cell numbers. Furthermore, Ad-PDA + Isl1b treatment activated several b cell-associated genes and consequently ameliorated hyperglycemia and improved glucose tolerance and responsiveness in diabetic mice. Therefore, we propose that Isl1b is required for the generation of glucose-responsive insulin-producing cells in the liver combined with PDA. Fig. 4(a)-4(c) . (a) mRNA levels of b cell markers: Pdx1, Neurod1, Mafa, Pax6, and Ucn3; a cell marker: Gcg. Endogenous Pdx1, Neurod1, and Mafa were detected using special primers, which amplified the 3 0 untranslated region indicated in Fig. 1(d) . (b) mRNA levels of b cell functional genes: Kir6.2, Pc2, Sur1, and Glut2. (c) mRNA levels of liver markers: Alb, Afp, and Hnf4a. LacZ indicates Ad-LacZ-injected liver (negative control) of MIP-GFP mice. Pancreatic islets (positive control) were isolated from adenovirus-untreated MIP-GFP mice. Primer sequences are summarized in Table 1 . All data (each group, n = 3) were analyzed by one-way analysis of variance followed by the TukeyKramer honest significant difference test. *P , 0.05; **P , 0.01. mRNA, messenger RNA; n.s., nonsignificant.
LBD of Isl1 is required to bind to LIM homeobox protein 3 (Lhx3), through which their transcriptional activity is increased (35, 36, 39) . Thus, Isl1b abolishes the synergistic transcriptional activity of Isl1/Lhx3 complex because of poor interaction with Lhx3 (35, 36, 39) . However, Isl1/ Lhx3 protein interaction occurs predominantly in neuronal tissues for driving neuro-differentiation and is rarely found in pancreatic islets (35, 36, 39) . Moreover, insulin transcriptional coactivators of Isl1, such as NeuroD (21, 22) and Hnf4a (40), do not require LBD for functional binding, thereby presumably maintaining the same function with Isl1b. Interestingly, LBD is also described for a transcriptional repressive role by folding of the Isl1 protein, which eventually hinders protein interactions with its cofactors (39) . Therefore, Isl1b is assumed to form less self-protein folding and to become more accessible to its binding partners, which in turn increases its transcriptional activity on target genes, allegedly insulin (35, 39) . Nevertheless, the same biological validity of Isl1b as Isl1 could not be determined in pancreatic islets, as Isl1b is exclusively expressed in b cell lines, whereas Isl1 is expressed in both a and b cells (35) . Furthermore, in our study we did not directly address whether hepatic NeuroD and Hnf4a interacted with Isl1b.
Interacting binding domains of Isl1 cofactors Ldb1 (20, 37) and SSBP3 (38) in islets have not been elucidated, and whether Isl1 is less potent than Isl1b in activating its target genes, such as Ins, Mafa, and Gcg, in liver has not been identified. Because Isl1b remains largely elusive, future studies of Isl1b function in pancreatic islets are needed to illuminate the more precise roles of Isl1b in b cell generation.
The extension of hepatic insulin transcriptional activities [ Fig. 3 ] and improved glucose responsiveness [ Fig.  6 (e)] could be attributed to changes in endogenous gene expression of the liver, given that adenoviral sustainability was unaffected by Isl1b addition. Evidently, many of the b cell signature genes, including Pdx1 and Neurod1, were endogenously induced in the Ad-PDA + Isl1b-treated liver [ Fig. 5(a) and 5(b) ], whereas the PDA-cell relied mostly on ectopic gene expression [ Fig. 1(c) and 1(e) ]. Because NeuroD can interact with either Pdx1 (41, 42) or Isl1 (21, 22) on the insulin promoter, more hepatic Pdx1 and NeuroD proteins would form abundant complexes of NeuroD/Pdx1 and NeuroD/Isl1b in the PDA + Isl1b liver. Consequently, the number of insulin-producing cells and the total insulin transcriptional activity were increased [ Fig. 4(d) and 4(e) ], emitting the peak signal at day 7. Fig. 6(d) . Data were analyzed by one-way ANOVA followed by the TukeyKramer HSD test. (e) In vivo glucose-stimulated insulin secretion assay at day 7 of adenovirus injection. Plasma was collected at 0 and 30 minutes of the glucose challenge. Data were analyzed by one-way ANOVA followed by the Tukey-Kramer HSD test. *P , 0.05; **P , 0.01; ***P , 0.001. ANOVA, analysis of variance; HSD, honest significant difference.
However, in the absence of Isl1b, a limited number of NeuroD/Pdx1 complexes were formed, producing the peak at day 3, which gradually faded at day 7 without additional Pdx1 and NeuroD proteins. Similarly, PDA + Isl1b and increased b cell functional genes [ Fig. 5(b) ] probably improved glucose responsiveness [ Fig. 6(e) ], as NeuroD can also contribute to regulation of insulin transcription, depending on different glucose concentrations, through changing its binding partners from Isl1 at low glucose levels to Pdx1 at high levels (41) .
Strikingly, previously reported neo-b cells in the liver generated by overexpressing either a single Ngn3 (Neurogenin-3, an endocrine progenitor marker) (43) or a combination of Pdx1, Ngn3, and Mafa (PNM) (44) were functional and exhibited drastically increased Isl1 level (43, 44) . Although the benefits of stable ectopic expression from use of immunodeficient mice (44) or an adeno-associated virus (43) could not be ignored, this could imply some degree of Isl1 contribution to functional b cell generation in the liver. However, the additional effects of Isl1b did not continue after 14 days, probably because of a prompt immune-mediated adenovirus clearance (Supplemental Fig. 1C) . Therefore, further study of the stable PDA + Isl1b system will elucidate whether functional hepatic insulin-producing cells can be maintained or not.
Uninhibited liver markers [ Fig. 5(c) ] were often reported in both direct (45) and stepwise (46) b cell reprogramming fields. Yang et al.'s (45) PNM-directed reprograming in the liver demonstrated that the Afp level was continuously higher and that Alb started to decrease below the control at 56 days of gene delivery. The inhibition of Alb was explained by maturing, reprogrammed insulin-producing cells, as glucose tolerance was first detected at day 56 (45) . Similarly, b cell differentiation of murine embryonic stem cells in culture exhibited gradual and significant increases of Alb and Hnf4a in parallel with Ins1/2 levels, which were also interpreted as immaturity (46) . In contrast, functional neo-b cells generated by permanent conversion in the liver did not express Alb and persevered b-like cell phenotype (43, 44) . From this, our addition of Isl1b can be said to initiate b cell conversion, which stopped before reaching the maturation process (i.e., thus a partial conversion). Because successful liver reprogramming was reported only in stable overexpression conditions (43, 44) , our partial conversion could have resulted from a transient expression system. Given that spontaneous Alb inhibition required 12 weeks (43, 44) , whether persistent expression of PDA + Isl1b eventually inhibits liver markers and promotes the beneficial effects warrants future studies.
Other pancreatic endoderm tissues, exocrine (47, 48) (47) . PNM overexpression of acinar cells lost amylase expression (47, 48) , exhibited glucose responsiveness, and importantly maintained the converted features (48) . In contrast, a cells, known for their high plastic epigenomic state, can be converted into b cells by a lower degree of gene manipulation (49) , such as (1) histone modification in vitro (49) or in vivo single-gene modification of either (2) Pax4 overexpression (50) or (3) Arx inhibition (51) in a cells. Although modification of the methylation pattern could not prevent glucagon coexpression in cultured islets (49), a cells from both genetically modified mice were successfully reprogrammed to functional b cells and maintained their newly adopted features under glucagon supplementation (50, 51) . Nevertheless, specifically targeting a cells (49) or exocrine cells (47, 48) is technically challenging because of the deep anatomic location of the pancreas and because a tissue-specific conditional knockout (51) or knock-in strategy (50) is not clinically actionable. Of note, the liver was effective at generating functional b cells through adenovirus-mediated gene transfer both permanently, as mentioned previously (43, 44) , and transiently (i.e., our Ad-PDA + Isl1b treatment). Moreover, commonly shared pancreatic progenitor Sox9 (44), large capacity, and a high proliferating rate of liver provide high tissue compatibility and targetability under intravenous injection of ectopic genes, bearing minimum invasiveness. Therefore, liver can be the most relevant extrapancreatic insulin-producing tissue for future clinical application.
Lastly, Elf3 (an E74-like ETS transcription factor 3) exhibited an unexpectedly extensive inhibition of insulin transcriptional activity by repressing PDA protein levels [ Fig. 2(g) ] but not transcriptional levels (Supplemental Fig. 2B ). This certainly sheds light on a new inhibitory mechanism of insulin production. It further raises the possibility that these 22 remaining nontranscriptional genes [ Fig. 2(e) ] might have multiple functionality on insulin production; for example, Ptprn (protein tyrosine phosphatase receptor type N) is identified as islet cells autoantigen of type I diabetes (52) . Future in vivo screening analysis will be essential to follow up on these candidates.
In summary, we propose that Isl1b is an essential insulinproducing factor in mouse liver, facilitating the Pdx1, Neuord1, and Mafa combination by increasing insulin production and glucose responsiveness through upregulation of b cell-related genes. Thus, these findings provide insight into the function of Isl1b as a therapeutic candidate for gene therapy through in vivo b cell generation to compensate for compromised b cell function in diabetes.
